A Single Dose-escalation Study of Cytisine in Adult Smokers

Achieve Life Sciences

Status and phase: Completed; Phase 1

Conditions: Smoking Cessation

Treatments: Drug: placebo; Drug: cytisine

Study type: Interventional

Funder types: Industry

Identifiers

NCT03848208

2018-003344-22 (EudraCT Number)

ACH-CYT-08

Details and patient eligibility

About

The objectives of this study are:

1. To assess the tolerability and safety of cytisine as a single oral dose.
2. To define the Cmax levels associated to the occurrence of dose-limiting adverse events.

Enrollment: 74 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Subjects must meet ALL of the following criteria to be eligible for inclusion into the study:

1. Free written informed consent prior to any procedure required by the study.
2. Male or female subjects, age ≥18 years, at the time of signing the informed consent.
3. Current daily cigarette smokers (averaging at least 10 cigarettes per day in the past 30 days).
4. Expired air carbon monoxide (CO) ≥10 ppm.
5. Able to swallow multiple tablets at one time.
6. Able to fully understand, comply with all study requirements.

Exclusion criteria

Subjects meeting ANY of the following exclusion criteria will NOT be eligible for inclusion into the study at screening.

1. Known hypersensitivity to cytisine or any of the excipients.

2. Known severe hypersensitivity to any other drug.

3. Positive urinary drugs of abuse screen, determined within 28 days before cytisine/placebo dosing.

4. Positive ethanol breath test.

5. Clinically significant abnormal serum chemistry, hematology, coagulation or urinalysis values within 28 days of randomization (i.e. requiring treatment or monitoring).

6. Clinically significant abnormalities in 12-lead echocardiogram (ECG) determined after minimum of 5 minutes in supine position within 28 days of randomization (i.e. requiring treatment or further assessment).

7. Body Mass Index (BMI) classification for being underweight (<18.5 kg/m2) or having ≥Class 2 obesity (≥35 kg/m2).

8. History of acute myocardial infarction, unstable angina, stroke, cerebrovascular incident, cardiac arrhythmia, or hospitalization for congestive heart failure.

9. Blood pressure ≥160/100 mmHg, measured on the dominant arm, after at least 3 minutes in supine position.

10. Creatinine clearance (CrCl) <80 mL/min (estimated with the Cockroft-Gault equation).

11. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.0 x the upper limit of normal (ULN).

12. Any inability to comply with study restrictions (See Section 9)

13. Any inability or difficulty in fasting.

14. Difficulty in donating blood on either arm.

15. If woman of childbearing potential, positive result in serum beta-human chorionic gonadotropin (hCG) pregnancy test.

16. Women who are breast-feeding.

17. Subjects who do not agree to use acceptable methods of birth control during the study (See Section 9.4).

18. Participation in a clinical study with an investigational drug within the previous 2 months.

19. Participation in more than 2 clinical trials within the previous 12 months.

20. Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.

    Subjects meeting ANY of the following exclusion criteria will NOT be eligible for inclusion into the study at admission to each cohort.

21. Any recent disease or condition or treatment that, according to the Investigator, would put the subject at undue risk due to study participation.

22. Positive urinary drugs of abuse screen.

23. Positive ethanol breath test.

24. If female of childbearing potential, positive result in urine beta-hCG pregnancy test.

25. Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

74 participants in 18 patient groups, including a placebo group

Cohort 1: Cytisine 6.0 mg

Experimental group

Description:

Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: cytisine

Cohort 1: Placebo

Placebo Comparator group

Description:

Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: placebo

Cohort 2: Cytisine 9.0 mg

Experimental group

Description:

Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: cytisine

Cohort 2: Placebo

Placebo Comparator group

Description:

Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: placebo

Cohort 3: Cytisine 12.0 mg

Experimental group

Description:

Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: cytisine

Cohort 3: Placebo

Placebo Comparator group

Description:

Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: placebo

Cohort 4: Cytisine 15.0 mg

Experimental group

Description:

Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: cytisine

Cohort 4: Placebo

Placebo Comparator group

Description:

Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: placebo

Cohort 5: Cytisine 18.0 mg

Experimental group

Description:

Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: cytisine

Cohort 5: Placebo

Placebo Comparator group

Description:

Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: placebo

Cohort 6: Cytisine 21.0 mg

Experimental group

Description:

Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: cytisine

Cohort 6: Placebo

Placebo Comparator group

Description:

Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: placebo

Cohort 7: Cytisine 24.0 mg

Experimental group

Description:

Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: cytisine

Cohort 7: Placebo

Placebo Comparator group

Description:

Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: placebo

Cohort 8: Cytisine 27.0 mg

Experimental group

Description:

Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: cytisine

Cohort 8: Placebo

Placebo Comparator group

Description:

Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: placebo

Cohort 9: Cytisine 30.0 mg

Experimental group

Description:

Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: cytisine

Cohort 9: Placebo

Placebo Comparator group

Description:

Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.

Treatment:

Drug: placebo